Iridium complexes inhibit tumor necrosis factor-α by utilizing light and mixed ligands

Elodie Sauvageot (1) , Pierre Lafite (2) , Eric Duverger (2, 3) , Ronan Marion (4) , Matthieu Hamel (5) , Sylvain Gaillard (1) , Richard Daniellou (2) , Jean-Luc Renaud (1)

1 LCMT - Laboratoire de chimie moléculaire et thioorganique
2 ICOA - Institut de Chimie Organique et Analytique
3 GLYcoDiag
4 FEMTO-ST - Franche-Comté Électronique Mécanique, Thermique et Optique - Sciences et Technologies (UMR 6174)
5 LCAE (CEA, LIST) - Laboratoire Capteurs et Architectures Electroniques (CEA, LIST)

We report herein a large study of the inhibition of tumor necrosis factor-α with 51 iridium(III) complexes, thus highlighting the influence of the nature of the ligands around the metal, their synergic effect and the role of the light.

Mots clés: WATER; Light; Tumour necrosis factor; Platinum Group Compounds; CATALYSIS; COPPER; METAL-COMPLEXES; ANTICANCER AGENTS; Cancer treatment; ORGANOMETALLIC COMPOUNDS; Cancer Therapy; Tumours; RUTHENIUM COMPLEXES; Iridium complexes; Inhibition; TNF-alpha

Domaines: Chimie organique; Catalyse; Cancer

Elodie Sauvageot, Pierre Lafite, Eric Duverger, Ronan Marion, Matthieu Hamel, et al.. Iridium complexes inhibit tumor necrosis factor-α by utilizing light and mixed ligands. Journal of Organometallic Chemistry, 2016, 808, pp.122-127. ⟨10.1016/j.jorganchem.2016.02.001⟩. ⟨cea-01847044⟩